At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 54 enrolled
Drug / intervention
ambrisentandrug
Likely dose
ambrisentan 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label, Long-Term Study of Ambrisentan in Pulmonary Hypertension Subjects Having Completed Myogen Study AMB-220
In Brief
A Phase 2 clinical trial evaluating ambrisentan for Pulmonary Hypertension. Completed, enrolled 54 participants.
Detailed Summary
AMB-220-E is an international, multicenter, open-label study examining the long-term safety of ambrisentan (BSF 208075) in subjects who have previously completed Myogen study NCT00046319, "A Phase II, Randomized, Double-Blind, Dose-Controlled, Dose-Ranging, Multicenter Study of BSF 208075 Evaluating Exercise Capacity in Subjects with Moderate to Severe Pulmonary Arterial Hypertension".
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPulmonary Hypertension
Countries--
Collaborators--
Timeline
Phase 2CompletedFinished
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartApr 2003
First PostedJan 2007
Primary CompletionDec 2009
TodayJul 2026
First PostedJan 18, 2007
Enrollment StartApr 1, 2003
Primary CompletionDec 1, 2009
TodayJul 2, 2026
Enrollment to primary: 6.7 yearsPosted 19.5 years ago
Interventions
ambrisentandrug
1, 2.5, 5, and 10 mg ambrisentan given orally once daily